|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Reduction of Antibiotic Therapy by Biomakers in Patients With CAP Episodes (REDUCE Study)
The purpose of this study is to evaluate two different treatment strategies in patients admitted to hospital with Community Acquired Pneumonia. The investigators hypothesize treatment according to both procalcitonin (PCT) and C-reactive protein (CRP) will be effective in reducing the length of antibiotic treatment.
100 Clinical Results associated with Pulmo BioTech, Inc.
0 Patents (Medical) associated with Pulmo BioTech, Inc.
100 Deals associated with Pulmo BioTech, Inc.
100 Translational Medicine associated with Pulmo BioTech, Inc.